AlloClae™™ is marketed as a source of ready-to-use, donor-derived volume. It is not a conventional filler or living fat transplant, and no one has directly studied whether GLP-1 therapy changes what happens after injection. In Part 1 of this series, we ended with an obvious question: if someone continues taking a GLP-1 medication after losing …
Continue reading “THE GLP-1 FILES, PART 2: Will the Fat Even Stay?”
There is a strange paradox taking shape in aesthetic medicine, predicated in large part by GLP-1 therapies for weight loss. No longer a niche treatment, a Gallup survey conducted in May and June 2026, reported that 11% of US adults are currently taking a GLP-1 medication for weight loss, up from 3% in 2024 [1]. …
Continue reading “THE GLP-1 FILES, PART 1: Digging Holes to Fill Them?”
A Higher Bar, A Wider Net: What ICH M14 and the New RWE Standards Mean for Medical Affairs In Part 1 of this series, we traced the arc from Frances Kelsey’s 1960 stand against anecdotal evidence to the emergence of real-world evidence as a formally recognized category of regulatory science. The story was one of …
Continue reading “RWE: From Regulatory Footnote to the Future of Medical Affairs, Part 2.”